

COMPLETION OF SHARE CONSOLIDATION

PYC Therapeutics (ASX:PYC) (PYC or the Company) advises that the consolidation of the Company's issued capital on a ten for one basis approved by shareholders at the Annual General Meeting on 13 November 2024 has completed.

The Company's post consolidation capital structure is as follows:

Class of securities	ASX Code	Exercise Price	Number
Ordinary Fully Paid	PYC	n/a	466,607,718
Unlisted Options Expiring 14 Feb 2027	PYCAE	\$1.70	150,000
Unlisted Options Expiring 28 Feb 2031	PYCAN	\$1.70	200,000
Unlisted Options Expiring 23 Mar 2031	PYCAO	\$1.70	250,000
Unlisted Options Expiring 23 Nov 2024	PYCAS	\$1.70	50,000
Unlisted Options Expiring 29 Mar 2031	PYCAQ	\$1.70	250,000
Unlisted Options Expiring 02 May 2026	PYCAU	\$1.70	240,000
Unlisted Options Expiring 26 Oct 2026	PYCAV	\$1.70	1,470,000
Unlisted Options Expiring 12 Oct 2027	PYCAW	\$0.90	350,000
Unlisted Options Expiring 22 May 2028	PYCAZ	\$1.70	2,100,000
Unlisted Options Expiring 01 Jul 2028	PYCAAA	\$1.70	200,000

New holding statements have been dispatched to shareholders on a post-consolidation basis.

Normal trading will commence on Tuesday 26 November 2024 under the code PYC.

For further information please refer to the Notice of General Meeting released on the ASX on 14 October 2024.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
Investor@pyctx.com